NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

TerminatedN/A

Sponsor: Sangamo Therapeutics

Conditions: Hemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II

Interventions: SB-318, SB-913, SB-FIX

Countries: United States

Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 10 years following exposure to SB-318, SB-913, or SB-FIX.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Subjects who received SB-318 under Study Protocol SB-318-1502, SB-913 under Study Protocol SB-913-1602, or SB-FIX under Study Protocol SB-FIX-1501
2. Subjects who have provided consent to participate in the LTFU study.

Exclusion Criteria:

1. Unable to comply with study visit schedule or study visit procedures.
2. Any other reason that, in the opinion of the Investigator or Medical Monitor, would render the subject unsuitable for participation in the study.

Locations (5)

Oakland, California, United States
Chicago, Illinois, United States
New York, New York, United States
Chapel Hill, North Carolina, United States
Cincinnati, Ohio, United States